Cited by 227Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.

Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC

Open access

Chu, Tianqing, Zhong, Runbo, Zhong, Hua, Zhang, Bo, Zhang, Wei, Shi, Chunlei, Qian, Jialin, Zhang, Yanwei, Chang, Qing, Zhang, Xueyan, Dong, Yu, Teng, Jiajun, Gao, Zhiqiang, Qiang, Huiping, Nie, Wei, Zhao, Yiming, Han, Yuchen, Chen, Ya, Han, Baohui·2021·Journal of Thoracic Oncology

DOI 10.1016/j.jtho.2020.11.026

Open this paper in CoChat — free account Open PDF

Abstract

Introduction Although the interaction between tumor immune microenvironment and angiogenesis has been well established, evidence supporting the chemo-free combination of immune checkpoint inhibitors plus antiangiogenic tyrosine kinase inhibitors in treatment-naive patients with advanced NSCLC is insufficient. This report provides the efficacy and safety of sintilimab combined with anlotinib as first-line therapy for advanced NSCLC from a phase 1b trial (NCT03628521).Methods Eligible patients who were treatment-naive and had unresectable stage IIIB/C or IV NSCLC without EGFR/ALK/ROS1 mutations received sintilimab (200 mg, day 1) and anlotinib (12 mg, day 1-14) every 3 weeks till disease progression or unacceptable toxicity. Baseline programmed death-ligand 1 expression and tumor mutation burden status was assessed in all patients. The primary end points were objective response rate and safety.Results A total of 22 patients received sintilimab and anlotinib. Median follow-up was 15.8 months (range: 8.3-19.3). Sixteen patients achieved confirmed partial response with an objective response rate of 72.7% (95% confidence interval [CI]: 49.8%-89.3%) and disease control rate of 100% (95% CI: 84.6%-100%). Median progression-free survival was 15 months (95% CI: 8.3 m, not reached), and the 12-month progression-free survival rate was 71.4% (95% CI: 47.2%-86.0%). The incidence rate of grade 3 or higher treatment-related adverse events was 54.5%, and grade 3 hypertension was predominant (two of 22, 9.1%). No grade 4 treatment-related adverse events were observed, and one case of grade 5 immune-related pneumonitis occurred.Conclusions To the best of our knowledge, this is the first study that assessed an anti-programmed cell death protein 1 antibody combined with a multitarget antiangiogenic tyrosine kinase inhibitor in the frontline setting for patients with NSCLC. In view of its encouraging efficacy, durability, and safety profile, sintilimab plus anlotinib represents a novel chemotherapy-free regimen in this patient population.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2020.11.026

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Mok, T. S. K., Wu, Y.-L. L. C., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., de Castro, G., Srimuninnimit, V., Лактионов, К. К., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,357
Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater
Reck, M., Rodríguez–Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00149 · Cited by 1,670
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
West, H., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H.-G., Daniel, D., McCune, S., Mekhail, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30167-6 · Cited by 1,662
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer
Gadgeel, S. M., Rodríguez‐Abreu, D., Speranza, G., Esteban, E., Felip, E., Dómine, M., Hui, R., Hochmair, M. J., Clingan, P. R., Powell, S. F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03136 · Cited by 1,124
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Reck, M., Mok, T. S. K., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez‐Abreu, D., Moro‐Sibilot, D., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30084-0 · Cited by 1,001

Show all 37 references

Sorted by citations

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Non‐small cell lung cancer in China
Chen, P., Liu, Y., Wen, Y., & Zhou, C. (2022) · 癌症：英文版 · doi:10.1002/cac2.12359 · Cited by 694
Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance
Wang, S., Wang, J., Chen, Z., Luo, J., Guo, W., Sun, L., & Lin, L. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00522-z · Cited by 657
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Naimi, A., Mohammed, R. N., Raji, A., Chupradit, S., Yumashev, A. V., Suksatan, W., Shalaby, M. N., Thangavelu, L. P., Kamrava, S., Shomali, N., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00854-y · Cited by 547
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Vafaei, S., Zekiy, A. O., Khanamir, R. A., Zaman, B. A., Ghayourvahdat, A., Azimizonuzi, H., & Zamani, M. (2022) · Cancer Cell International · doi:10.1186/s12935-021-02407-8 · Cited by 284
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects
Tang, S., Qin, C., Hu, H., Liu, T., He, Y., Guo, H., Yan, H., Zhang, J., Tang, S., & Zhou, H. (2022) · Cells · doi:10.3390/cells11030320 · Cited by 273
New clinical trial design in precision medicine: discovery, development and direction
Duan, X.-P., Qin, B., Jiao, X., Liu, K., Wang, Z., & Zang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01760-0 · Cited by 225
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1–Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial
Xu, Q., Wang, J., Sun, Y., Lin, Y., Liu, J., Zhuo, Y., Huang, Z., Huang, S., Chen, Y., Chen, L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02091 · Cited by 157
Self-citation
Anlotinib Induces a T Cell–Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma
Su, Y., Luo, B., Lu, Y., Wang, D., Yan, J. Y., Zheng, J., Xiao, J. H., Wang, Y., Xue, Z., Yin, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2241 · Cited by 153
Novel strategies for cancer immunotherapy: counter-immunoediting therapy
Liu, S., Sun, Q., & Ren, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01430-8 · Cited by 107
Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis
Lei, T., Xu, T., Zhang, N., Zou, X., Kong, Z., Wei, C., & Wang, Z. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106668 · Cited by 66
Emerging biomaterials for tumor immunotherapy
Xiao, M., Tang, Q., Zeng, S., Yang, Q., Yang, X., Tong, X., Zhu, G., Lei, L., & Li, S. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00369-8 · Cited by 65
Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents
Singh, T., Hassanabad, M. F., & Hassanabad, A. F. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188636 · Cited by 54
Anlotinib potentiates anti‐PD1 immunotherapy via transferrin receptor‐dependent CD8 + T‐cell infiltration in hepatocellular carcinoma
Song, F., Hu, B., Liang, X., Cheng, J., Wang, C., Wang, P., Wang, T., Tang, P., Sun, H., Guo, W., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1738 · Cited by 55
Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities
Wang, H., Niu, X., Jin, Z., Zhang, S., Fan, R., Xiao, H., & Hu, S. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03519-z · Cited by 72
Novel Targets, Novel Treatments: The Changing Landscape of Non-Small Cell Lung Cancer
de Jong, D., Das, J. P., Ma, H., Valiplackal, J. P., Prendergast, C. M., Roa, T., Braumuller, B., Deng, A., Dercle, L., Yeh, R., et al. (2023) · Cancers · doi:10.3390/cancers15102855 · Cited by 55
Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis
Zhou, J., Sun, Y., Zhang, W., Yuan, J., Peng, Z., Wang, W., Gong, J., Yang, L., Cao, Y., Zhao, H., et al. (2022) · Hepatology · doi:10.1002/hep.32548 · Cited by 52
Self-citation
A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer
Chen, B., Yao, W., Li, X., Lin, G., Chu, Q., Liu, H., Du, Y., Lin, J., Duan, H., Wang, H., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02519-0 · Cited by 43
Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study
Chen, X., Li, W., Wu, X., Zhao, F., Wang, D., Wu, H., Gu, Y., Li, X., Qian, X., Hu, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.909035 · Cited by 43
Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer
Wei, W., Ban, X., Yang, F., Li, J., Cheng, X., Zhang, R., Huang, X., Huang, Y., Li, Q., Qiu, Y., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004338 · Cited by 40
Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer
Choi, S. H., Yoo, S. S., Lee, S. Y., & Park, J. Y. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01382-6 · Cited by 40
Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial
Zhou, H., Zhang, Y., Chen, G., Yu, Q.-T., Zhang, H., Wu, G., Wu, D., Lin, Y., Zhu, J., Chen, J., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01927-9 · Cited by 40
Self-citation
Sintilimab for the treatment of non-small cell lung cancer
Zhang, L., Lin, W., Tan, F., Li, N., Xue, Q., Gao, S., Gao, Y., & He, J. (2022) · Biomarker Research · doi:10.1186/s40364-022-00363-7 · Cited by 36
Efficacy and safety of anlotinib combined with PD ‐1/ PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer
Yu, L., Xu, J., Qiao, R., Han, B., Zhong, H., & Zhong, R. (2022) · Cancer Medicine · doi:10.1002/cam4.5360 · Cited by 38
Self-citation
Feasibility and tolerability of sintilimab plus anlotinib as the second‐line therapy for patients with advanced biliary tract cancers: An open‐label, single‐arm, phase II clinical trial
Jin, S., Zhao, R., Zhou, C., Zhong, Q., Shi, J., Su, C., Li, Q., Su, X., Chi, H., Lu, X., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34372 · Cited by 33
Self-citation
Microbiota-derived urocanic acid triggered by tyrosine kinase inhibitors potentiates cancer immunotherapy efficacy
Zhang, M., Wei, Z., Wei, B., Lai, C., Zong, G., Tao, E., Fan, M., Pan, Y., Zhou, B., Shen, L., et al. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.04.022 · Cited by 32
Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer
Xiong, Q., Qin, B., Xin, L., Yang, B. Y., Song, Q., Wang, Y., Zhang, S., & Hu, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.659380 · Cited by 33
The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
Zeng, Z., Qian, X., Liu, F., Wang, Y., Yuan, Y., Chen, F., Zhang, X., Yuan, S., Chen, R., Yu, B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956982 · Cited by 31
Self-citation
Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial
Han, X., Guo, J., Li, L., Huang, Y., Meng, X., Wang, L., Zhu, H., Meng, X., Shao, Q., Li, X., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01957-3 · Cited by 30
Self-citation
A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world
Shi, Y. X., Ji, M., Jiang, Y., Yin, R. L., Wang, Z., Li, H., Wang, S., He, K., Ma, Y., Wang, Z., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-350 · Cited by 30
A phase II study of sintilimab, anlotinib, and pegaspargase sandwiched with radiotherapy as first‐line therapy in patients with newly diagnosed, stage I–II extranodal natural‐killer/T‐cell lymphoma
Sun, P., Li, Y., Li, C., Ren, K., Wang, Y., Yang, H., Jiang, W., Zou, L., Yang, H., Zhou, H., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.26922 · Cited by 26
Immune Checkpoint Inhibitor Combined with Antiangiogenic Agent Synergistically Improving the Treatment Efficacy for Solid Tumors
Zhou, Y. J., Liu, Z., Yu, A., Zhao, G., & Chen, B. (2024) · ImmunoTargets and Therapy · doi:10.2147/itt.s494670 · Cited by 30
Multi‐target angiogenesis inhibitor combined with PD ‐1 inhibitors may benefit advanced non‐small cell lung cancer patients in late line after failure of EGFR‐TKI therapy
Yu, L., Hu, Y., Xu, J., Qiao, R., Zhong, H., Han, B., Xia, J., & Zhong, R. (2023) · International Journal of Cancer · doi:10.1002/ijc.34536 · Cited by 27
Self-citation
Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma
Tang, H. J., You, T., Ge, H., Gao, J., Wang, Y., Bai, C., Sun, Z., Han, Q., & Zhao, R. C. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112053 · Cited by 26
Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: a phase 2 investigator-initiated non-randomized controlled trial
Ma, S., He, Z., Liu, Y., Wang, L., Yang, S., Wu, Y., Chen, H., Wu, Y., & Wang, Q. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102543 · Cited by 25
Resistance to immunotherapy in non-small cell lung cancer: Unraveling causes, developing effective strategies, and exploring potential breakthroughs
Dong, S., Li, X., Huang, Q., Li, Y., Li, J., Zhu, X., Xue, C., Chen, R., Zeng, Y., Wu, J., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101215 · Cited by 25
Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
Ren, S., He, J., Fang, Y., Chen, G., Ma, Z., Chen, J., Guo, R., Lin, X., Yao, Y., Wu, G., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100312 · Cited by 24
Combination of Immune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer
Fang, L., Zhao, W., Ye, B., & Chen, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670313 · Cited by 23
Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy
Kiasari, B. A., Abbasi, A., Darestani, N. G., Adabi, N., Moradian, A., Yazdani, Y., Hosseini, G. S., Gholami, N., & Janati, S. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109365 · Cited by 26
Brain metastases and lung cancer: molecular biology, natural history, prediction of response and efficacy of immunotherapy
Sereno, M., de Córdoba, I. H., Gutiérrez‐Gutiérrez, G., & Casado, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1297988 · Cited by 23
Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review
Wu, S., Wu, S., Liao, X., Zhou, C., Qiu, F. X., Wang, C., & Zhong, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1274937 · Cited by 22
Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives
Zhao, Y., Liu, L., & Weng, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.714483 · Cited by 24
Self-citation
Increasing the tumour targeting of antitumour drugs through anlotinib-mediated modulation of the extracellular matrix and the RhoA/ROCK signalling pathway
Han, X., Liu, J., Zhang, Y., Tse, E., Yu, Q., Yu, L., Ma, Y., & Zheng, L. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.100984 · Cited by 21
Self-citation
Neoadjuvant therapy in triple-negative breast cancer: A systematic review and network meta-analysis
Lin, Y., Gao, H., Yang, X., Zhu, T., Zheng, X., Ji, F., Zhang, L., Yang, C.-Q., Yang, M., Li, J., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.08.006 · Cited by 23
Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer
He, D., Wang, L., Xu, J., Zhao, J., Bai, H., & Wang, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1265865 · Cited by 21
Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC
Wang, S., Lou, N., Luo, R., Hao, X., Liu, Y., Wang, L., Shi, Y., & Han, X. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03451-2 · Cited by 20
Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients
Yuan, S., Peng, L., Liu, Y., Till, B. G., Yan, X., Zhang, J., Zhu, L., Wang, H., Zhang, S., Li, H., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03259-5 · Cited by 19
Therapeutic targeting of VEGF and/or TGF-β to enhance anti-PD-(L)1 therapy: The evidence from clinical trials
Li, L., Wen, Q., & Ding, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.905520 · Cited by 19
Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study
Chu, T., Zhang, W., Zhang, B., Zhong, R., Zhang, X., Gu, A., Shi, C., Wang, H., Xiong, L., Lü, J., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-438 · Cited by 19
Self-citation
The war between the immune system and the tumor - using immune biomarkers as tracers
Yang, K., Lu, R., Mei, J., Cao, K., Zeng, T., Hua, Y., Huang, X., Li, W., & Yin, Y. (2024) · Biomarker Research · doi:10.1186/s40364-024-00599-5 · Cited by 22
Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial (TD-NeoFOUR trial)
Duan, H., Shao, C., Luo, Z., Wang, T., Tong, L., Liu, H., Yao, X., Lei, J., Zhao, J., Gao, Y., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01992-0 · Cited by 20
Synergizing Success: The Role of Anlotinib Combinations in Advanced Non-Small Cell Lung Cancer Treatment
Hetta, ‏. F., Aljohani, H. M., Sirag, N., Elfadil, H., Salama, A., Al-Twalhy, R., Alanazi, D. A., Aljohani, M. M., Albalawi, J. H., Al-Otaibi, R. M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18040585 · Cited by 19
Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer
Mussafi, O., Mei, J., Mao, W., & Wan, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.948405 · Cited by 19
Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies
Gao, R.-L., Song, J., Sun, L., Wu, Z.-X., Yi, X.-F., Zhang, S., Huang, L., Ma, J., & Han, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.920165 · Cited by 18
Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study
Dou, X.-J., Ma, R.-Y., Ren, D.-W., Liu, Q., & Yan, P. (2024) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s444884 · Cited by 16
Toripalimab plus anlotinib in patients with recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm phase 2 trial (TORAL)
Zhang, Y., Zou, Q., Zhao, B., Su, N., Li, Z., Wang, X., Liu, P., Tian, X., Fang, X., Cai, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101833 · Cited by 19
Self-citation
Butyrophilin-like 9 expression is associated with outcome in lung adenocarcinoma
Ma, W., Liang, J., Mo, J., Zhang, S., Hu, N., Tian, D., & Chen, Z. (2021) · BMC Cancer · doi:10.1186/s12885-021-08790-9 · Cited by 16
Normalization of tumor vasculature: A potential strategy to increase the efficiency of immune checkpoint blockades in cancers
Shi, Y., Li, Y., Wu, B., Zhong, C., Lang, Q., Liang, Z., Zhang, Y., Lv, C., Han, S., Yu, Y., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108968 · Cited by 17
Self-citation
Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: a retrospective comparative cohort study
Yu, L., Xu, J., Qiao, R., Zhong, H., Brueckl, W. M., & Zhong, R. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-260 · Cited by 15
Self-citation
A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancer
Zhang, W. J., Wang, J., Wang, Q., Cheng, Y., Yang, L., Li, Y., Zhong, H., Chu, T., Dong, Y., Zhang, Y., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107353 · Cited by 15
Self-citation
Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases
Yang, G., Xing, L., & Sun, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.852811 · Cited by 15
Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study
Wang, W., Shao, L., Xu, Y., Song, Z., Lou, G., Zhang, Y., & Chen, M. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-01981-5 · Cited by 15
Self-citation
Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients
Feng, Y., Tang, L. M., Wang, H., Liu, Y., Yang, S., Lin, L., Hu, X., & Shi, Y. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03251-z · Cited by 13
Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer
Li, L., Pu, H., Zhang, X., Guo, X., Li, G., & Zhang, M. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104683 · Cited by 16
Self-citation
The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
Wang, F., Jin, F., Cheng, B., Zhang, Y., Zhou, Q. H., & Wang, S. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03752-x · Cited by 14
Self-citation
Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase “Sandwich” With Radiotherapy in Localized Natural Killer/T Cell Lymphoma
Sun, P., Wang, Y., Yang, H., Chen, C., Nie, M., Sun, X., He, X., Huang, K.-M., Huang, J., & Li, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.766200 · Cited by 14
Drug Repurposing to Circumvent Immune Checkpoint Inhibitor Resistance in Cancer Immunotherapy
To, K. K. W., & Cho, W. C. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082166 · Cited by 16
Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study
Liu, Y., Ge, Q., Xu, S., Li, K., & Liu, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.942678 · Cited by 13
Anlotinib reduces the suppressive capacity of monocytic myeloid-derived suppressor cells and potentiates the immune microenvironment normalization window in a mouse lung cancer model
Zhao, X., Zhao, R., Wen, J., Zhang, X., Wu, S., Fang, J., Ma, J., Zheng, W., Zhang, X., Lu, Z., et al. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001481 · Cited by 13
Self-citation
Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer
Lv, W., Pei, X., Zhao, W., Cong, Y., Wei, Y., Li, T., Zhang, H., Zhong, L., Saito, Y., Kim, J. J., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-49 · Cited by 12
Pan‐cancer efficacy and safety of anlotinib plus PD ‐1 inhibitor in refractory solid tumor: A single‐arm, open‐label, phase II trial
Qin, B., Jiao, X., Wang, Z., Liu, K., Wu, Y., Ling, Y., Chen, S., Zhong, X., Duan, X., Qin, W., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34546 · Cited by 12
Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial
Chen, K., Xu, Y., Huang, Z., Yu, X., Hong, W., Li, H., Xu, X., Lu, H., Xie, F., Chen, J., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6548 · Cited by 13
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial
Ren, S., Wang, X., Han, B., Pan, Y., Zhao, J., Cheng, Y., Hu, S., Liu, T., Li, Y., Cheng, Y., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007227 · Cited by 13
Self-citation
Benmelstobart plus anlotinib in patients with EGFR-positive advanced NSCLC after failure of EGFR TKIs therapy: a phase I/II study
Shi, M., Chen, P., Cui, B., Yao, Y., Wang, J., Zhou, T., & Wang, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01982-2 · Cited by 12
Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC
Huang, H., Zhong, P., Zhu, X., Fu, S., Li, S., Peng, S., Liu, Y., Lu, Z., & Chen, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1137224 · Cited by 12
Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study
Ma, K., Guo, Q., & Li, X. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02470-z · Cited by 12
Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial
Meng, X., Yang, X., Hong, Y., Wang, W., Zhang, Z., Xia, J., Chen, Y., Zhou, Y., Lu, T., Song, M. S., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02376-w · Cited by 11
Self-citation
Neoadjuvant anlotinib/sintilimab plus chemotherapy in triple-negative breast cancer (NeoSACT): Phase 2 trial
Zhang, L., Yang, L., Ge, Y., Zhu, Z., Chen, B., Yang, C., Gao, H., Yang, M., Zhu, T., & Wang, K. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102193 · Cited by 11
Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial
Chu, T., Zhong, H., Yu, Z., Wang, J., Zhao, Y., Mu, X., Yu, X., Shi, X., Shi, Q., Guan, M., et al. (2025) · 癌症：英文版 · doi:10.1002/cac2.12654 · Cited by 11
Self-citation
Advances in the Management of Central Nervous System Metastases in Non-Small Cell Lung Cancer
D’Aiello, A., Miao, E., & Cheng, H. (2023) · Cancers · doi:10.3390/cancers15030844 · Cited by 13
Targeting Angiogenesis in the Era of Biliary Tract Cancer Immunotherapy: Biological Rationale, Clinical Implications, and Future Research Avenues
Schirizzi, A., Leonardis, G. D., Lorusso, V., Donghia, R., Rizzo, A., Vallarelli, S., Ostuni, C., Troiani, L., Lolli, I. R., Giannelli, G., et al. (2023) · Cancers · doi:10.3390/cancers15082376 · Cited by 11
Anlotinib reversed resistance to PD-1 inhibitors in recurrent and metastatic head and neck cancers: a real-world retrospective study
Jiang, J., Wu, B., Sun, Y., Xiang, J., Shen, C., He, X., Ying, H., & Xia, Z. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03784-5 · Cited by 10
Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial
Shen, Y., Lü, J., Hu, F., Qian, J., Zhang, X., Zhong, R., Zhong, H., Chu, T., & Han, B. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-03964-9 · Cited by 10
Self-citation
Current status and future of anti-angiogenic drugs in lung cancer
Yan, X., Zhao, Z., & Tang, H. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01039-8 · Cited by 10
Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances
Dehghani, T., Shahrjerdi, A., Kahrizi, M. S., Soleimani, E., Ravandeh, S., Merza, M. S., Rahnama, N., Ebrahimzadeh, F., & Bakhshesh, M. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154470 · Cited by 10
Anti-PD-1 therapy achieves favorable outcomes in HBV-positive non-liver cancer
Zhou, J., Chen, G., Wang, J., Zhou, B., Sun, X., Wang, J., Tang, S., Xing, X., Hu, X., Zhao, Y., et al. (2023) · Oncogenesis · doi:10.1038/s41389-023-00468-0 · Cited by 10
Self-citation
Durable Response to Immunotherapy With Antiangiogenic Drug in Large-Cell Lung Carcinoma With Multiple Fulminant Postoperative Metastases: A Case Report
Luo, Z., Zhang, H., Xiao, Y., Wang, R., Zhang, L., Huang, C., Cao, Y. Q., Sun, C., Zhao, Y., Lin, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.633446 · Cited by 10
Self-citation
Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer
Cheng, Y., Li, H., Zhang, L., Liu, J., Yang, C., & Zhang, S. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001560 · Cited by 10
Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study
Pu, X., Lin, G., Xiao, M., Lin, J., Wang, Q., Kong, Y., Yan, X., Xu, F., Xu, Y., Li, J., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102403 · Cited by 9
Landscape of the clinical development of China innovative anti-lung cancer drugs
Shi, Y. (2022) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2022.10.003 · Cited by 11
Feasibility and tolerability of anlotinib plus PD-1 blockades as rechallenge immunotherapy in previously treated advanced ESCC: a retrospective study
Hong, Y., Liu, J., Lu, P., Zhi-wei, C., Zhang, G., Ma, X., Wei, L., Tian, Y., Xia, J., Cao, H., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae245 · Cited by 9
Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review
Piao, M., Ma, X., Tankéré, P., Liam, C. K., Li, J., & Wang, J. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-4312 · Cited by 9
A novel prediction model for the prognosis of non-small cell lung cancer with clinical routine laboratory indicators: a machine learning approach
Wang, Y., Mei, N., Zhou, Z., Fang, Y., Lin, J., Zhao, F., Fang, Z., & Yan, L. (2024) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-024-02753-3 · Cited by 8
Sintilimab Plus Axitinib for Advanced Fumarate Hydratase–Deficient Renal Cell Carcinoma
Zhang, X., Liu, H., Liang, J., Zhao, J., Wang, Y., Chen, Y., Kang, D., Chen, Q., Zhang, Y., Yin, X., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.2497 · Cited by 9
Self-citation
Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review
Liu, Z., Yu, M., Zhao, F. H., & Zhu, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.976415 · Cited by 8
Comparison of cardiotoxicity induced by alectinib, apatinib, lenvatinib and anlotinib in zebrafish embryos
Liu, J., Li, W., Sun, S., Huang, L., Wan, M., Li, X., Zhang, L., Yang, D., Liu, F., Liao, X., et al. (2024) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2024.109834 · Cited by 8
Incidence of thromboembolic events in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
Yang, M., Cao, H., Wang, C., Yu, C., & Sun, P. (2024) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1031_23 · Cited by 9
Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Epithelial Ovarian Cancer: A Retrospective Study
Li, X.-Y., Rao, Y., Sun, B., & Mao, X.-M. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s352536 · Cited by 8
Immune Modulatory Effects of Molecularly Targeted Therapy and Its Repurposed Usage in Cancer Immunotherapy
Zhang, T., Zhang, C., Fu, Z., & Gao, Q. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091768 · Cited by 8

Authors: Chu, T., Zhong, R., Zhong, H., Zhang, B., Zhang, W., Shi, C., Qian, J., Zhang, Y., Chang, Q., Zhang, X., Dong, Y., Teng, J., Gao, Z., Qiang, H., Nie, W., Zhao, Y., Han, Y., Chen, Y., & Han, B.
Affiliations: Shanghai Jiao Tong University (CN)
Corresponding author: Han, Baohui
ORCID: Chu, Tianqing
Zhong, Runbo
Zhong, Hua
Zhang, Bo
Zhang, Wei
Shi, Chunlei
Qian, Jialin
Zhang, Yanwei
Chang, Qing
Zhang, Xueyan
Dong, Yu
Teng, Jiajun
Gao, Zhiqiang
Nie, Wei
Zhao, Yiming
Han, Yuchen
Chen, Ya
Han, Baohui
Venue: Journal of Thoracic Oncology
Publisher: Elsevier BV
Published: 2021-04
Volume: 16
Issue: 4
Pages: 643-652
ISSN: 1556-0864 (ISSN-L)
DOI: 10.1016/j.jtho.2020.11.026
OpenAlex: W3126928179
Cited by: 227
References: 37
Citations by year: 2026: 11 · 2025: 35 · 2024: 56 · 2023: 53 · 2022: 54 · 2021: 17
FWCI: 16.38
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
Locations: Journal of Thoracic Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: Science and Technology Commission of Shanghai Municipality (18411968500)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: sintilimab, anlotinib, non-small cell lung cancer, first-line therapy, immune checkpoint inhibitors, antiangiogenic tyrosine kinase inhibitors, anti-PD-1 therapy, combination immunotherapy, chemotherapy-free regimen, tumor immune microenvironment, tumor angiogenesis, objective response rate, progression-free survival, treatment-related adverse events, hypertension, immune-related pneumonitis, PD-L1 expression
MeSH terms: Antineoplastic Combined Chemotherapy Protocols, Humans, Indoles, Lung Neoplasms, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Quinolines, Tumor Microenvironment, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks